European Urology Open Science最新文献

{"title":"Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer","authors":"Ursula Lemberger ,&nbsp;Büsra Ernhofer ,&nbsp;Sigurd Krieger ,&nbsp;Andreas Bruchbacher ,&nbsp;André Oszwald ,&nbsp;Ekaterina Laukhtina ,&nbsp;Andrea Haitl ,&nbsp;Melanie R. Hassler ,&nbsp;Bernhard Englinger ,&nbsp;Eva Compérat ,&nbsp;Shahrokh F. Shariat","doi":"10.1016/j.euros.2024.10.022","DOIUrl":"10.1016/j.euros.2024.10.022","url":null,"abstract":"<div><h3>Background and objective</h3><div>The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alteration patterns with DNA damage and response to therapy.</div></div><div><h3>Methods</h3><div>Matched tissue from 46 patients with MIBC was investigated via Ion Torrent–based next-generation sequencing using a self-designed panel of 30 DDR genes. Phosphorylation of γ-histone 2A.X (H2AX) was analyzed via immunohistochemistry to evaluate DNA damage. Genetic variants were analyzed along with clinical data and quantitative phospho-H2AX data using the Kaplan-Meier method, Cox regression analysis, and factor analysis of mixed data.</div></div><div><h3>Key findings and limitations</h3><div>Twenty-five patients (54%) had a response (&lt;pT2 pN0 cM0) to NAC. Responders had more somatic DDR gene variants in preNAC (53 vs 11; <em>p</em> &lt; 0.001) and postNAC (51 vs 9; <em>p</em> = 0.038) tumor tissue in comparison to nonresponders, as well as significantly greater phosphorylation of H2AX after NAC. <em>ERCC2</em> was significantly co-mutated with <em>REV3L</em> among responders. Owing to the small cohort, no specific mutation was significantly positively associated with therapy response. However, accumulation of <em>CDK12</em>, <em>NBN</em>, <em>MSH3</em>, <em>MLH1</em>, <em>ATR</em>, <em>BRCA1</em>, <em>BRCA2</em>, <em>REVL3L</em>, and <em>SLX4</em> variants was observed for responders.</div></div><div><h3>Conclusions and clinical implications</h3><div>Patients with MIBC who responded to cisplatin-based NAC had more somatic DDR gene variants than nonresponders. Moreover, responders exhibited significantly greater DNA damage after NAC.</div></div><div><h3>Patient summary</h3><div>Patients with muscle-invasive bladder cancer who have mutations in genes that are involved in repair of DNA damage are more likely to respond to cisplatin-based chemotherapy. Testing to identify these gene mutations could help in selecting the patients who are most likely to benefit from this treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 38-48"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer","authors":"Madison T. Baxter ,&nbsp;Christopher C. Conlin ,&nbsp;Aditya Bagrodia ,&nbsp;Tristan Barrett ,&nbsp;Hauke Bartsch ,&nbsp;Anja Brau ,&nbsp;Matthew Cooperberg ,&nbsp;Anders M. Dale ,&nbsp;Arnaud Guidon ,&nbsp;Michael E. Hahn ,&nbsp;Mukesh G. Harisinghani ,&nbsp;Juan F. Javier-DesLoges ,&nbsp;Sophia C. Kamran ,&nbsp;Christopher J. Kane ,&nbsp;Joshua M. Kuperman ,&nbsp;Daniel J.A. Margolis ,&nbsp;Paul M. Murphy ,&nbsp;Nabih Nakrour ,&nbsp;Michael A. Ohliger ,&nbsp;Rebecca Rakow-Penner ,&nbsp;Tyler M. Seibert","doi":"10.1016/j.euros.2024.12.003","DOIUrl":"10.1016/j.euros.2024.12.003","url":null,"abstract":"<div><div>Multiparametric magnetic resonance imaging (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, the major limitations are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to address these issues include use of biparametric magnetic resonance imaging (bpMRI) and advanced, quantitative magnetic resonance imaging (MRI) techniques. One such advanced technique is the Restriction Spectrum Imaging restriction score (RSIrs), an imaging biomarker that has been shown to improve quantitative accuracy of patient-level csPCa detection. Advanced Restriction imaging and reconstruction Technology for Prostate MRI (ART-Pro) is a multisite, multinational trial that aims to evaluate whether IV contrast can be avoided in the setting of standardized, state-of-the-art image acquisition, with or without addition of RSIrs. Additionally, RSIrs will be evaluated as a stand-alone, quantitative, objective biomarker. ART-Pro will be conducted in two stages and will include a total of 500 patients referred for multiparametric prostate MRI with a clinical suspicion of prostate cancer at the participating sites. ART-Pro-1 will evaluate bpMRI, mpMRI, and RSIrs on the accuracy of expert radiologists’ detection of csPCa and will evaluate RSIrs as a stand-alone, quantitative, objective biomarker. ART-Pro-2 will evaluate the same MRI techniques on the accuracy of nonexpert radiologists’ detection of csPCa, and findings will be evaluated against the expertly created dataset from ART-Pro-1. The primary endpoint is to evaluate whether bpMRI is noninferior to mpMRI among expert (ART-Pro-1) and nonexpert (ART-Pro-2) radiologists for the detection of grade group ≥2 csPCa. This trial is registered in the US National Library of Medicine Trial Registry (NCT number: NCT06579417) at ClinicalTrials.gov. Patient accrual at the first site (UC San Diego) began in December 2023. Initial results are anticipated by the end of 2026.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 132-143"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor","authors":"Ben-Max de Ruiter ,&nbsp;Jan E. Freund ,&nbsp;C. Dilara Savci-Heijink ,&nbsp;Jons W. van Hattum ,&nbsp;Marinka J. Remmelink ,&nbsp;Theo M. de Reijke ,&nbsp;Joyce Baard ,&nbsp;Guido M. Kamphuis ,&nbsp;D. Martijn de Bruin ,&nbsp;Jorg R. Oddens","doi":"10.1016/j.euros.2024.11.007","DOIUrl":"10.1016/j.euros.2024.11.007","url":null,"abstract":"<div><h3>Background and objective</h3><div>Urothelial bladder cancer (UCB) care requires frequent follow-up cystoscopy and surgery. Confocal laser endomicroscopy (CLE), a probe-based optical technique for real-time microscopic evaluation, has shown promising accuracy for grading of UCB. We investigated the diagnostic accuracy of CLE-based assessment of the surgical radicality of the bladder resection bed (RB).</div></div><div><h3>Methods</h3><div>We prospectively included 40 participants scheduled for transurethral resection of bladder tumors (TURBT) in two academic hospitals. Exclusion criteria were flat lesions, fluorescein allergy, and pregnancy. We performed CLE of the RB during TURBT. Histopathology of an RB biopsy was the reference test. Results at first cystoscopy 3 mo after TURBT are reported. A panel of two blinded observers evaluated the CLE images. The diagnostic accuracy of CLE for detection of detrusor muscle (DM) and residual tumor (rT) was calculated using 2 × 2 tables.</div></div><div><h3>Key findings and limitations</h3><div>Histopathology for 22 CLE-matched RB biopsies revealed rT in four cases (18%) and DM in 13 (59%). The quality of CLE imaging was low in four (18%), moderate in 16 (73%), and good in two (9%) cases. CLE was able to correctly predict rT in two of the four cases (50%) identified on histopathology. The sensitivity, specificity, positive predictive value, and negative predictive value were 0.5 (95% confidence interval [CI] 0.07–0.93), 0.83 (95% CI 0.59–0.96), 0.4 (95% CI 0.05–0.85), and 0.88 (95% CI 0.64–0.99) for CLE prediction of rT, and 0.69 (95% CI 0.39–0.91), 0.33 (95% CI 0.07–0.7), 0.6 (95% CI 0.32–0.84), and 0.43 (95% CI 0.1–0.82) for prediction of DM, respectively. Five patients (23%) had rT at 3-mo follow-up; CLE had predicted rT in three, and histopathology had revealed rT in two cases at TURBT.</div></div><div><h3>Conclusions and clinical implications</h3><div>CLE does not appear to be a reliable tool for detecting rT or DM in the RB after TURBT.</div></div><div><h3>Patient summary</h3><div>We investigated a special imaging technique called confocal laser endomicroscopy (CLE) for checking the bladder after surgery for bladder cancer in a group of 40 patients. CLE results were compared to traditional biopsy results and the patients were checked after 3 months. CLE was not very reliable in detecting any remaining cancer (only 50% accurate) or important muscle tissue in the surgical area, and the quality of the images varied. While CLE shows some promise, it is not currently a dependable method for evaluating the bladder after bladder cancer surgery.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 57-62"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"21 FBXW7 loss-of-function is associated with worse overall survival and leads to the accumulation of MYC in muscle-invasive bladder cancer","authors":"Black P.,&nbsp;Matsumoto T.,&nbsp;Wang R.,&nbsp;Chen E.,&nbsp;Roberts M.,&nbsp;Reike M.,&nbsp;Ikeda K.,&nbsp;Oo H.Z.,&nbsp;Sano T.,&nbsp;LeBlanc E.,&nbsp;Singh K.,&nbsp;Gao J.,&nbsp;Moskalev I.,Contreras-Sanz A.","doi":"10.1016/S2666-1683(25)00025-4","DOIUrl":"10.1016/S2666-1683(25)00025-4","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S24"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Evaluation of Morbidity and Predictors of Response to Imiquimod Treatment for Penile Intraepithelial Neoplasia","authors":"Ofir Avitan ,&nbsp;Laura Elst ,&nbsp;Manon Vreeburg ,&nbsp;Tynisha Rafael ,&nbsp;Katja Jordanova ,&nbsp;Niels Graafland ,&nbsp;Kees Hendricksen ,&nbsp;Bas W.G. van Rhijn ,&nbsp;Henk G. van der Poel ,&nbsp;Maarten Albersen ,&nbsp;Oscar Brouwer","doi":"10.1016/j.euros.2024.08.020","DOIUrl":"10.1016/j.euros.2024.08.020","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Imiquimod (IQ) is an immunomodulator used in the management of penile intraepithelial neoplasia (PeIN) lesions. However, IQ treatment may be associated with bothersome side effects (SEs). To date, studies reporting on this morbidity and evaluating predictors of response to IQ are scarce and included small cohorts. The primary objective of our study was to assess the response to IQ treatment, associated SEs, and potential predictors of response in the largest reported cohort to date.</div></div><div><h3>Methods</h3><div>We conducted a collaborative retrospective study involving patients diagnosed with PeIN and treated with IQ between 2010 and 2022 in two high-volume centers in the Netherlands and Belgium. Eligible patients had a confirmed diagnosis of PeIN and a minimum of 6-mo follow-up. Response to IQ was categorized as a complete response (CR), partial response, or no response. Descriptive statistics were generated and statistical tests included the Mann-Whitney U test for age and Fisher’s exact test for categorical variables.</div></div><div><h3>Key findings and limitations</h3><div>The study included a total of 44 patients, with a median age of 65.4 yr (interquartile range 56–72). Of these patients, 28 (64%) achieved a CR, while 14 (32%) had a partial response and two (4.5%) had no response. In the CR subgroup, the 3-yr recurrence rate was 25%. No significant correlation was found between response status and age, human papillomavirus status, history of penile cancer, or circumcision before treatment. Among the patients, 50% reported SEs, mainly local pain, irritation, and bleeding, and 12% discontinued treatment because of SEs. There was no significant correlation between CR and the incidence or type of SE.</div></div><div><h3>Conclusions and clinical implications</h3><div>Despite the high overall response rate to IQ, a significant number of patients experienced local recurrence within 3 yr, and approximately half of the patients reported SEs. Our results did not identify any clinical or pathological factors or local SEs predictive of the therapeutic response to IQ. Prospective studies are needed to help in predicting which patients are likely to respond to IQ so that those who will not benefit can be spared the SEs associated with this treatment.</div></div><div><h3>Patient summary</h3><div>Our study looked at responses to imiquimod (IQ), an immune-based treatment in cream format, for precancerous lesions on the penis, called penile intraepithelial neoplasia. More than 95% of patients had a complete or partial response to IQ, but 50% reported side effects, and 25% of the group with a complete response had recurrence within 3 years. More research is needed to help in selecting patients who will benefit the most from IQ treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 63-68"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1 SMART GRAFT: Surgeon’s expertise and Machine learning Automated biopsy Reading Towards improving GRaft Assessment For Transplant","authors":"Figueiredo A.J.,&nbsp;Silva E.M.C.T.,&nbsp;Rodrigues L.M.A.,&nbsp;Nunes P. T. C.,&nbsp;Marconi L.S.O.,&nbsp;Retroz E.A.C.,&nbsp;Eliseu M.N.C.,&nbsp;Jarimba R.L.S.,Marques M.J.G.,&nbsp;Leal A.R.G.C.,&nbsp;Santos L.S.,&nbsp;Romaozinho C.P.R.M.,&nbsp;Sousa V.M.L.,&nbsp;Parada B.A.C.","doi":"10.1016/S2666-1683(25)00012-6","DOIUrl":"10.1016/S2666-1683(25)00012-6","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S1"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"13 Oncological and functional outcomes of robot-assisted radical prostatectomy in low-riskprostate cancer patients eligible for active surveillance","authors":"Govorov A.,&nbsp;Pushkar D.","doi":"10.1016/S2666-1683(25)00016-3","DOIUrl":"10.1016/S2666-1683(25)00016-3","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S14"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3 Obesity and kidney stones","authors":"Kørting K.,&nbsp;Jensen L.S.,&nbsp;Øbro L.F.,&nbsp;Osther S.S.,&nbsp;Andreassen K.H.,&nbsp;Osther P.J.S.","doi":"10.1016/S2666-1683(25)00034-5","DOIUrl":"10.1016/S2666-1683(25)00034-5","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S2"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial","authors":"Federica Sordelli ,&nbsp;Antonio Desai ,&nbsp;Filippo Dagnino ,&nbsp;Roberto Contieri ,&nbsp;Sofia Giuriolo ,&nbsp;Marco Paciotti ,&nbsp;Vittorio Fasulo ,&nbsp;Stefano Mancon ,&nbsp;Davide Maffei ,&nbsp;Pier Paolo Avolio ,&nbsp;Giorgio Da Rin ,&nbsp;Federica Maura ,&nbsp;Elena Vanni ,&nbsp;Davide Federico ,&nbsp;Piergiuseppe Colombo ,&nbsp;Giovanni Lughezzani ,&nbsp;Nicolò Maria Buffi ,&nbsp;Paolo Casale ,&nbsp;Alberto Saita ,&nbsp;Massiomo Lazzeri ,&nbsp;Antonio Voza","doi":"10.1016/j.euros.2024.09.001","DOIUrl":"10.1016/j.euros.2024.09.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bladder cancer (BC) represents a significant health care challenge and is frequently detected during evaluations for haematuria in emergency departments (EDs). Our aim was to evaluate the clinical performance and economic implications of the Xpert BC Detection (BCD) test for patients presenting to the ED with haematuria to address the pressing need for more efficient and accurate diagnostic tools in this setting.</div></div><div><h3>Methods</h3><div>We conducted a prospective single-centre observational study in the ED of a tertiary university hospital. Patients presenting with gross haematuria as the primary reason for their visit were enrolled. Urine samples collected in the ED were analysed using the Xpert BCD test. The primary outcomes were sensitivity, specificity, and a cost analysis for the Xpert BCD test in comparison to standard diagnostic methods such as urine cytology (UC) and white-light cystoscopy (WLC).</div></div><div><h3>Key findings and limitations</h3><div>The Xpert BCD test exhibited superior sensitivity to UC, particularly in identifying high-grade tumours. Importantly, Xpert BCD implementation has the potential to significantly reduce the number of unnecessary WLC procedures and streamline diagnostic pathways. The cost analysis also highlighted potential cost savings for Xpert BCD adoption in the ED setting.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our findings underscore the promise of Xpert BCD for revolutionising the diagnostic approach to BC in the ED for patients with gross haematuria. Its greater sensitivity and efficiency mean that Xpert BCD has the potential to improve patient care, optimise resource use, and alleviate the economic burden associated with unnecessary procedures.</div></div><div><h3>Patient summary</h3><div>Xpert Bladder Cancer Detection is a simple urine test that detects the presence of five genes associated with bladder cancer. We found that for patients visiting the emergency department because of blood in their urine, use of this test could save time and money over urine cell analysis (UCA) for ruling out or diagnosing bladder cancer. The test was also more sensitive in detecting higher-grade cancers. More research is needed to confirm our results.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 172-179"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Performance and Activity in Older Prostate Cancer Survivors in Comparison with Population-based Matched Controls","authors":"Reidun Sletten ,&nbsp;Marit Slaaen ,&nbsp;Line Merethe Oldervoll ,&nbsp;Håvard Kjesbu Skjellegrind ,&nbsp;Jūratė Šaltytė Benth ,&nbsp;Lennart Åstrøm ,&nbsp;Øyvind Kirkevold ,&nbsp;Sverre Bergh ,&nbsp;Bjørn Henning Grønberg ,&nbsp;Siri Rostoft ,&nbsp;Asta Bye ,&nbsp;Paul Jarle Mork ,&nbsp;Ola Berger Christiansen","doi":"10.1016/j.euros.2024.11.005","DOIUrl":"10.1016/j.euros.2024.11.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>Whether radical prostate cancer treatment affects long-term physical performance and physical activity in older men is not known. We aimed to compare physical performance and self-reported physical activity between relapse-free older prostate cancer survivors and population-based controls.</div></div><div><h3>Methods</h3><div>A single-centre, cross-sectional study including 109 men aged ≥70 yr receiving robotic-assisted radical prostatectomy (61.5%) or external beam radiotherapy (38.5%) between 2014 and 2018 was conducted. Population-based matched (age, gender, and education) controls (<em>n</em> = 327) were drawn from the Trøndelag Health Study. The primary (the Short Physical Performance Battery [SPPB] summary score) and secondary (gait speed, grip strength, one-legged balance, and the self-reported Physical Activity Index) outcomes were compared between survivors and controls by adjusted linear mixed models.</div></div><div><h3>Key findings and limitations</h3><div>The SPPB score, gait speed, and Physical Activity Index did not differ between survivors (mean age 78.3 yr, mean time since treatment 52.9 mo) and controls (mean age 78.2 yr). Survivors had slightly poorer grip strength (regression coefficient [RC] –5.81, <em>p</em> &lt; 0.001, 95% confidence interval [CI] –7.46; –4.17) and one-legged balance (RC –4.36, <em>p</em> &lt; 0.001, 95% CI –6.72; –2.00; adjusted models), but the clinical significance is uncertain. Small sample size and potential selection of the fittest survivors are limitations that may reduce the generalisability of our findings.</div></div><div><h3>Conclusions and clinical implications</h3><div>3 to 8 yr after radical prostate cancer treatment, older men’s overall physical performance and physical activity level were comparable with those of matched controls. This suggests that the treatment had little impact on functional status.</div></div><div><h3>Patient summary</h3><div>In this study, we investigated physical function in older men several years after they had undergone curatively intended treatment for prostate cancer in comparison with men in a general population of the same age and education. We found that physical function was similar, except slightly poorer grip strength and balance on one leg in men treated for prostate cancer. We conclude that the overall physical function was comparable with that of the general population and believe that this indicates that prostate cancer treatment was well tolerated despite older age.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 87-95"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}